# A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis

> **NCT07465120** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Dermavon Holdings Limited** · enrollment: 160 (estimated)

## Conditions studied

- Moderate to Severe Atopic Dermatitis

## Interventions

- **DRUG:** CMS-D001 50mg
- **DRUG:** CMS-D001 100mg
- **DRUG:** CMS-D001 200mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07465120
- **Lead sponsor:** Dermavon Holdings Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-20
- **Primary completion:** 2027-01-31
- **Final completion:** 2027-05-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07465120

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07465120, "A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase Ⅱ Clinical Study to Evaluate the Efficacy and Safety of CMS-D001 in Adult Patients With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07465120. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*